Serum cytokine profiling identifies IL-17A and IL-10 as prognostic biomarkers for disease outcome in pediatric acute lymphoblastic leukemia

IF 4.1 3区医学 Q2 IMMUNOLOGY

Clinical immunology Pub Date : 2026-01-01 Epub Date: 2025-11-07 DOI:10.1016/j.clim.2025.110638

Qian Ye , Jin Rao , Li Zhang , Muxia Yan , Huishan Chen , Yanping Yi , Hua Jiang , Xiaoliang Deng , Yiqian Wang

{"title":"Serum cytokine profiling identifies IL-17A and IL-10 as prognostic biomarkers for disease outcome in pediatric acute lymphoblastic leukemia","authors":"Qian Ye , Jin Rao , Li Zhang , Muxia Yan , Huishan Chen , Yanping Yi , Hua Jiang , Xiaoliang Deng , Yiqian Wang","doi":"10.1016/j.clim.2025.110638","DOIUrl":null,"url":null,"abstract":"<div><div>Pediatric acute lymphoblastic leukemia (ALL) is the most common childhood malignancy, yet reliable serum biomarkers for prognosis and relapse prediction remain limited. We profiled serum cytokines in 60 pediatric ALL patients and 19 healthy controls using the Aimplex Cytokine Assay, and evaluated predictive performance via receiver operating characteristic (ROC) analysis and least absolute shrinkage and selection operator (LASSO) regression. ALL patients exhibited significantly elevated levels of IFN-γ, IL-2, IL-4, IL-10, IL-17A, and TNF-α compared with controls. Among these, IL-17A and IL-10 showed the strongest associations with disease severity and relapse risk, with higher baseline levels correlating with increased relapse probability (<em>p</em> = 0.02 and <em>p</em> = 0.005) and longer time to achieve remission in multivariate LASSO models. These findings identify IL-17A and IL-10 as promising prognostic biomarkers for pediatric ALL, with potential application in risk stratification and guiding individualized treatment strategies.</div></div>","PeriodicalId":10392,"journal":{"name":"Clinical immunology","volume":"282 ","pages":"Article 110638"},"PeriodicalIF":4.1000,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical immunology","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S152166162500213X","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/11/7 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"IMMUNOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Pediatric acute lymphoblastic leukemia (ALL) is the most common childhood malignancy, yet reliable serum biomarkers for prognosis and relapse prediction remain limited. We profiled serum cytokines in 60 pediatric ALL patients and 19 healthy controls using the Aimplex Cytokine Assay, and evaluated predictive performance via receiver operating characteristic (ROC) analysis and least absolute shrinkage and selection operator (LASSO) regression. ALL patients exhibited significantly elevated levels of IFN-γ, IL-2, IL-4, IL-10, IL-17A, and TNF-α compared with controls. Among these, IL-17A and IL-10 showed the strongest associations with disease severity and relapse risk, with higher baseline levels correlating with increased relapse probability (p = 0.02 and p = 0.005) and longer time to achieve remission in multivariate LASSO models. These findings identify IL-17A and IL-10 as promising prognostic biomarkers for pediatric ALL, with potential application in risk stratification and guiding individualized treatment strategies.

Abstract Image

查看原文本刊更多论文

血清细胞因子分析确定IL-17A和IL-10是儿童急性淋巴细胞白血病疾病结局的预后生物标志物。

小儿急性淋巴细胞白血病（ALL）是最常见的儿童恶性肿瘤，但可靠的血清生物标志物预后和复发预测仍然有限。我们使用Aimplex细胞因子测定法分析了60名儿科ALL患者和19名健康对照者的血清细胞因子，并通过受试者工作特征（ROC）分析和最小绝对收缩和选择算子（LASSO）回归来评估预测效果。与对照组相比，ALL患者的IFN-γ、IL-2、IL-4、IL-10、IL-17A和TNF-α水平显著升高。其中，IL-17A和IL-10与疾病严重程度和复发风险的相关性最强，在多变量LASSO模型中，较高的基线水平与复发概率增加相关（p = 0.02和p = 0.005），并且实现缓解的时间更长。这些发现确定了IL-17A和IL-10是儿科ALL的预后生物标志物，在风险分层和指导个体化治疗策略方面具有潜在的应用前景。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Clinical immunology 医学-免疫学

CiteScore

12.30

自引率

1.20%

发文量

212

审稿时长

34 days

期刊介绍： Clinical Immunology publishes original research delving into the molecular and cellular foundations of immunological diseases. Additionally, the journal includes reviews covering timely subjects in basic immunology, along with case reports and letters to the editor.